Increase in R & D capacity in Exbio Praha (Q9626)

From EU Knowledge Graph
Revision as of 14:52, 22 October 2020 by DG Regio (talk | contribs) (‎Created claim: summary (P836): The aim of the project is to increase the capacity of the R & D of Exbio Praha, a.s., especially in the field of new monoclonal antibodies and their derivatives, directly labelled monoclonal antibodies for use in flow cytometry. These will serve for further development of new diagnostic kits for use in diagnostic (human model) or scientific laboratories (animal model). Resolving the project objectives will enable the company to develop a portfol...)
Jump to navigation Jump to search
Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Increase in R & D capacity in Exbio Praha
Project in Czech Republic financed by DG Regio

    Statements

    0 references
    15,522,939.0 Czech koruna
    0 references
    620,917.56 Euro
    10 January 2020
    0 references
    31,045,878.0 Czech koruna
    0 references
    1,241,835.12 Euro
    10 January 2020
    0 references
    50 percent
    0 references
    15 June 2015
    0 references
    4 June 2018
    0 references
    14 June 2018
    0 references
    EXBIO Praha, a.s.
    0 references
    0 references

    49°58'5.20"N, 14°32'56.36"E
    0 references

    49°58'14.12"N, 14°31'52.07"E
    0 references
    25242
    0 references
    Cílem projektu je zvýšení kapacit vlastního VaV společnosti EXBIO Praha, a.s. především v oblasti nových monoklonálních protilátek a jejich derivátů, přímo značených monoklonálních protilátek pro použití v průtokové cytometrii. Tyto budou sloužit pro další vývoj nových diagnostických souprav pro použití v diagnostických (lidský model) nebo vědeckých laboratořích (zvířecí model). Vyřešení cílů projektu umožní firmě rozvinout portfolio vlastních výrobků a prosadit se na vysoce konkurenčních trzích (Czech)
    0 references
    The aim of the project is to increase the capacity of the R & D of Exbio Praha, a.s., especially in the field of new monoclonal antibodies and their derivatives, directly labelled monoclonal antibodies for use in flow cytometry. These will serve for further development of new diagnostic kits for use in diagnostic (human model) or scientific laboratories (animal model). Resolving the project objectives will enable the company to develop a portfolio of its own products and to assert itself in highly competitive markets (English)
    22 October 2020
    0 references

    Identifiers

    CZ.01.1.02/0.0/0.0/15_002/0000480
    0 references